Eisai-Mylan Tango for Second Halaven Brand In India But Eyes On Pricing, Generics

Eisai has struck a deal with Mylan for a second brand of Halaven in India, joining a growing list of foreign firms deploying this approach to expand access to novel therapies in the country amid emerging competition.

Holding_Arrow
Mylan To Market Second Brand Of Eisai's Halaven In India • Source: Shutterstock

Eisai Co. Ltd., has firmed up a licensing deal with Mylan NV for a second brand of Halaven (eribulin mesylate), as the Japanese company seeks to expand availability and access to the anticancer on the Indian market amid the recent arrival of a cut-price rival.

The licensing agreement will see Mylan India promote and distribute the second brand, Teceris, in the country, with eribulin being...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from India

More from Focus On Asia